Clinical Trial Update: Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 dose-range study of anamorelin in patients with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anamorelin (anamorelin)

Snippet

Sponsor: Helsinn Therapeutics (U.S.), Inc | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED